首頁 > 市場調查報告書 > 製藥

囊腫纖維化治療藥物市場規模、佔有率和成長分析（按藥物類別、給藥途徑、分銷管道和地區分類）—產業預測（2026-2033 年）

市場調查報告書

商品編碼

1898045

囊腫纖維化治療藥物市場規模、佔有率和成長分析（按藥物類別、給藥途徑、分銷管道和地區分類）—產業預測（2026-2033 年）

Cystic Fibrosis Therapeutics Market Size, Share, and Growth Analysis, By Drug Class (CFTR Modulators, Pancreatic Enzyme Supplements), By Route Of Administration (Oral, Inhaled), By Distribution Channel, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月17日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計囊腫纖維化治療市場規模在 2024 年將達到 74.2 億美元，從 2025 年的 84.7 億美元成長到 2033 年的 243.2 億美元，在預測期（2026-2033 年）內複合年成長率為 14.1%。

囊腫纖維化（CF）盛行率的不斷上升，以及治療率的提高，顯著推動了對治療方案的需求。主要市場促進因素包括私營和政府部門研發投入的增加、非營利主導的增多以及支持性的報銷政策。患者數量的成長與對有效CF治療方法（包括CF藥物、支氣管擴張劑、祛痰藥和各種抗生素）日益成長的需求密切相關。此外，各大製藥公司正在研發的藥物製劑種類日益豐富，也促進了市場成長。致力於CF的慈善機構，例如CF Worldwide和囊性纖維化組織，透過資助研發，在推動囊腫纖維化治療進展和拓展市場方面發揮關鍵作用。

囊腫纖維化治療市場促進因素

囊腫纖維化治療市場成長的關鍵因素之一是囊性纖維化盛行率的上升。囊腫纖維化是一種影響呼吸系統、消化器官系統和生殖系統的遺傳性疾病。此疾病為慢性且無法治愈，患者需終身接受持續治療。因此，人們對能夠有效控制症狀並提高患者生活品質的囊腫纖維化治療方法的需求日益成長。隨著醫療服務提供者和患者尋求應對這種複雜疾病相關挑戰的解決方案，創新治療方法的持續需求進一步推動了市場擴張。

囊腫纖維化治療市場限制因素

囊腫纖維化治療，尤其是創新標靶治療的高昂費用，嚴重阻礙了患者獲得治療。這種經濟負擔引發了人們對這些藥物成本效益的質疑，並可能限制他們獲得所需治療的能力。此外，這些治療方法的高昂價格也給醫療系統帶來壓力，並引發了人們對更廣泛患者群體治療永續性和可及性的擔憂。因此，成本仍然是囊腫纖維化治療市場面臨的一項重大挑戰，對患者和醫療服務提供者都造成了影響。

囊腫纖維化治療市場趨勢

在基因研究進展的推動下，囊腫纖維化治療市場正呈現出顯著的個人化醫療趨勢。對導致囊腫纖維化的各種基因突變的深入了解，加速了針對個別患者需求的客製化治療方法的推出。這種向精準醫療的轉變正在推動創新，製藥公司致力於開發標靶治療，以提高治療效果並改善患者預後。隨著新療法的不斷湧現，醫療服務提供者和患者都將積極接受這種個人化醫療模式，從而鞏固其在不斷發展的囊腫纖維化治療領域中的重要地位。

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較
主要企業簡介
- Vertex Pharmaceuticals（美國）
- 艾伯維（美國）
- 吉利德科學公司（美國）
- 羅氏（瑞士）
- 梯瓦製藥工業（以色列）
- 邁蘭（現為維亞特里斯）（美國）
- 諾華公司（瑞士）
- 阿斯特捷利康（英國）
- Alaxia
- 艾爾建（現為艾伯維旗下公司）（愛爾蘭）
- Beyond Air Inc.（美國）
- F. Hoffmann-La Roche Ltd.（瑞士）
- 默克公司（美國）
- Alcresta Therapeutics Inc.（美國）
- 基耶西（義大利）
- 雀巢健康科學（瑞士）
- Pharmaxis有限公司（澳洲）
- PTC Therapeutics, Inc.（美國）
- Insmed公司（美國）
- 格里福爾斯公司（西班牙）

結論與建議

簡介目錄

Product Code: SQMIG35I2224

Cystic Fibrosis Therapeutics Market size was valued at USD 7.42 Billion in 2024 and is poised to grow from USD 8.47 Billion in 2025 to USD 24.32 Billion by 2033, growing at a CAGR of 14.1% during the forecast period (2026-2033).

The growing prevalence of cystic fibrosis (CF) significantly fuels the demand for therapeutic solutions, alongside increasing treatment rates. Key market drivers include enhanced R&D investment from both private and government sectors, an uptick in nonprofit-driven initiatives, and supportive reimbursement policies. This rising patient population correlates with heightened demand for effective CF therapies, including CFTR modulators, bronchodilators, mucolytics, and various antibiotic formulations. Additionally, the expanding range of drug compositions in development among leading pharmaceutical players contributes to market growth. Charitable organizations dedicated to CF, such as CF Worldwide and the Cystic Fibrosis Organization, play a crucial role by funding research and development efforts, further propelling advancements in cystic fibrosis therapeutics and expanding the market landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Cystic Fibrosis Therapeutics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Cystic Fibrosis Therapeutics Market Segments Analysis

Global Cystic Fibrosis Therapeutics Market is segmented by Drug Class, Route Of Administration, Distribution Channel and region. Based on Drug Class, the market is segmented into Anti-infectives, CFTR Modulators, PancreaticenzymeSupplements, Mucolytics and Bronchodilators. Based on Route Of Administration, the market is segmented into Oral and Inhaled. Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Cystic Fibrosis Therapeutics Market

A significant factor propelling the cystic fibrosis therapeutics market is the rising incidence of cystic fibrosis, a genetic disorder that impacts the respiratory, digestive, and reproductive systems. This condition is both chronic and incurable, necessitating continuous treatment throughout a patient's life. As a result, there is a growing demand for effective cystic fibrosis therapies to manage symptoms and improve the quality of life for those affected. The ongoing need for innovative treatment options in this area further fuels market expansion, as healthcare providers and patients seek solutions to navigate the challenges associated with this complex disease.

Restraints in the Cystic Fibrosis Therapeutics Market

The elevated expenses associated with cystic fibrosis treatments, especially the innovative targeted therapies, present a significant obstacle to patient access. This financial burden raises important questions regarding the affordability of these medications for many individuals, potentially limiting their ability to receive necessary care. Furthermore, the high prices of these therapies can strain healthcare systems, creating concerns about sustainability and accessibility for a broader patient population. As a result, the cost factor remains a critical challenge within the cystic fibrosis therapeutics market, affecting both patients and healthcare providers alike.

Market Trends of the Cystic Fibrosis Therapeutics Market

The cystic fibrosis therapeutics market is witnessing a notable trend towards personalized medicine, driven by advancements in genetic research. With a deeper understanding of the various mutations that cause cystic fibrosis, there is an increasing push for tailored treatment options that effectively address individual patient needs. This shift towards precision therapy is fostering innovation, as pharmaceutical companies focus on developing targeted therapies that enhance treatment efficacy and patient outcomes. As new treatments emerge, healthcare providers and patients alike are expected to embrace these personalized approaches, solidifying the trend's significance in the evolving landscape of cystic fibrosis care.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Analysis
Technology Analysis

Global Cystic Fibrosis Therapeutics Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Anti-infectives
CFTR Modulators
Pancreatic Enzyme Supplements
Mucolytics
Bronchodilators

Global Cystic Fibrosis Therapeutics Market Size by Route Of Administration & CAGR (2026-2033)

Market Overview
Oral
Inhaled

Global Cystic Fibrosis Therapeutics Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Global Cystic Fibrosis Therapeutics Market Size & CAGR (2026-2033)

North America (Drug Class, Route Of Administration, Distribution Channel)
- US
- Canada
Europe (Drug Class, Route Of Administration, Distribution Channel)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Drug Class, Route Of Administration, Distribution Channel)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Drug Class, Route Of Administration, Distribution Channel)
- Brazil
- Rest of Latin America
Middle East & Africa (Drug Class, Route Of Administration, Distribution Channel)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Vertex Pharmaceuticals (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan (now Viatris) (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alaxia.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergan (now part of AbbVie) (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Beyond Air Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F. Hoffmann-La Roche Ltd. (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co. Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Alcresta Therapeutics Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Chiesi (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Nestle HealthScience (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pharmaxis Ltd. (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
PTC Therapeutics, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Insmed, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Grifols S.A. (Spain)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments